Physician profile
Aliena Gomes
NPI 1316593304
$1,152.91
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $190 · 2023: $278 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $194.84 | 2021-2022 | |
| Seagen INC. | $131.38 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $112.13 | 2021-2024 | Opdivo |
| Neurocrine Biosciences, INC. | $110.06 | 2023 | |
| Celgene Corporation | $95.54 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $94.87 | 2021-2023 | Breztri, Farxiga |
| Amgen INC. | $60.36 | 2021 | |
| Lilly USA, LLC | $52.35 | 2023-2024 | Emgality, Jardiance, Mounjaro |
| Pharmacyclics LLC, An Abbvie Company | $46.86 | 2022 | |
| Gilead Sciences, INC. | $27.79 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.56 | 2024 | Xifaxan |
| Jazz Pharmaceuticals INC. | $21.98 | 2021 | |
| Glaxosmithkline, LLC. | $20.96 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $20.32 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Deciphera Pharmaceuticals INC. | $19.71 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.02 | 2024 | Spravato |
| Acrotech Biopharma INC. | $18.03 | 2022 | |
| Daiichi Sankyo INC. | $17.29 | 2024 | Enhertu |
| Pfizer INC. | $14.61 | 2021 | |
| Cranial Technologies, INC | $13.42 | 2023 | Doc Band |
| Genzyme Corporation | $12.72 | 2021 | |
| Astellas Pharma US INC | $12.55 | 2021 | |
| Clovis Oncology, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliena Gomes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.